©2024 Stanford Medicine
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Not Recruiting
Trial ID: NCT03949517
Purpose
This study is being conducted to determine whether the combination of imaging agents 68-Ga
RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound
(HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with
known prostate cancer.
Official Title
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion Criteria:
- Known prostate cancer
- Planned HIFU or HDR local therapy
- Able to provide written consent
- Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG)
/World Health Organization (WHO) equivalent)
Exclusion Criteria:
- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Intervention(s):
drug: 68-Ga RM2
drug: 68-Ga PSMA11
device: Investigational software and coils in PET/MR Scan
procedure: PET/MRI
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brittney Williams
650-736-3688